2011
Evaluation of NT-proBNP and high sensitivity C-reactive protein for predicting cardiovascular risk in patients with arthritis taking longterm nonsteroidal antiinflammatory drugs.
Ruff CT, Morrow DA, Jarolim P, Ren F, Contant CF, Kaur A, Curtis SP, Laine L, Cannon CP, Brune K. Evaluation of NT-proBNP and high sensitivity C-reactive protein for predicting cardiovascular risk in patients with arthritis taking longterm nonsteroidal antiinflammatory drugs. The Journal Of Rheumatology 2011, 38: 1071-8. PMID: 21459935, DOI: 10.3899/jrheum.100880.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnti-Inflammatory Agents, Non-SteroidalArthritis, RheumatoidBiomarkersC-Reactive ProteinCardiovascular DiseasesDiclofenacEtoricoxibFemaleHeart FailureHumansLongitudinal StudiesMaleMiddle AgedMyocardial InfarctionNatriuretic Peptide, BrainOsteoarthritisPeptide FragmentsProspective StudiesPyridinesRetrospective StudiesRisk FactorsSulfonesThrombosisTreatment OutcomeConceptsHigh-sensitivity C-reactive proteinNonsteroidal antiinflammatory drugsSensitivity C-reactive proteinNT-proBNPC-reactive proteinHeart failureCV eventsCV outcomesCV riskThrombotic eventsMyocardial infarctionAntiinflammatory drugsBiomarkers N-terminal pro-B-type natriuretic peptideCardiac biomarkers N-terminal pro-B-type natriuretic peptideN-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptideChronic nonsteroidal antiinflammatory drugsBaseline NT-proBNPChronic NSAID treatmentLow CV riskNT-proBNP levelsFuture cardiovascular eventsBody mass indexIdentification of patientsTypes of arthritis
2008
Management of Patients on Nonsteroidal Anti-inflammatory Drugs: A Clinical Practice Recommendation From the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents
Chan FK, Abraham NS, Scheiman JM, Laine L. Management of Patients on Nonsteroidal Anti-inflammatory Drugs: A Clinical Practice Recommendation From the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents. The American Journal Of Gastroenterology 2008, 103: ajg2008576. PMID: 18853980, DOI: 10.1111/j.1572-0241.2008.02200.x.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNonselective nonsteroidal antiinflammatory drugsNonsteroidal antiinflammatory drugsGI risk factorsNonsteroidal anti-inflammatory drugsCV riskHigh CV riskProton pump inhibitorsAnti-inflammatory drugsRisk factorsCyclooxygenase-2- selective nonsteroidal antiinflammatory drugsSelective nonsteroidal antiinflammatory drugsCardiovascular safety issuesMultidisciplinary international panelPatient's CV riskClinical practice recommendationsManagement of patientsAnti-platelet agentsGI complicationsCardiovascular effectsGI riskInternational working partyPump inhibitorsTreatment strategiesAntiinflammatory drugsPatientsCOX-2 Selective Inhibitors in the Treatment of Osteoarthritis
Laine L, White WB, Rostom A, Hochberg M. COX-2 Selective Inhibitors in the Treatment of Osteoarthritis. Seminars In Arthritis And Rheumatism 2008, 38: 165-187. PMID: 18177922, DOI: 10.1016/j.semarthrit.2007.10.004.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsTraditional nonsteroidal antiinflammatory drugsNonsteroidal antiinflammatory drugsTreatment of osteoarthritisBlood pressureNonselective nonsteroidal antiinflammatory drugsCyclooxygenase-2 selective inhibitorCOX-2 selective inhibitorsClinical liver injuryHepatic side effectsSignificant renal dysfunctionCongestive heart failureSelective inhibitorAminotransferase elevationClinical hepatotoxicityGastrointestinal complicationsHypertensive patientsRenal dysfunctionUlcer complicationsCardiovascular riskSevere painGastroduodenal ulcersHeart failureLiver injuryOA patientsRandomized trials
2000
Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis
Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz M, Hawkey C, Hochberg M, Kvien T, Schnitzer T. Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis. New England Journal Of Medicine 2000, 343: 1520-1528. PMID: 11087881, DOI: 10.1056/nejm200011233432103.Peer-Reviewed Original ResearchMeSH KeywordsAdultArthritis, RheumatoidCardiovascular DiseasesCyclooxygenase 2Cyclooxygenase 2 InhibitorsCyclooxygenase InhibitorsDuodenal ObstructionFemaleGastric Outlet ObstructionGastrointestinal DiseasesGastrointestinal HemorrhageHumansIsoenzymesLactonesMaleMembrane ProteinsMiddle AgedNaproxenPeptic UlcerProportional Hazards ModelsProstaglandin-Endoperoxide SynthasesSulfonesConceptsUpper gastrointestinal eventsNonselective nonsteroidal antiinflammatory drugsGastrointestinal eventsRheumatoid arthritisCyclooxygenase-2Upper gastrointestinal toxicityPercent of patientsPrimary end pointOverall mortality rateNonsteroidal antiinflammatory drugsRate of deathYears of ageNonselective NSAID naproxenSelective inhibitorCardiovascular causesRofecoxib groupGastrointestinal toxicityNaproxen groupMyocardial infarctionSimilar efficacyAntiinflammatory drugsLower incidenceArthritisMortality ratePatients
1996
Medical Treatment of Peptic Ulcer Disease: Practice Guidelines
Soll A, Achord J, Bozymski G, Brooks S, Lanza F, Lyon D, Meyer G, Reinus J, Schuster M, Achord J, Ofman J, Glassman P, Laine L, Tytgat G, Walsh J, Graham D, Peterson W. Medical Treatment of Peptic Ulcer Disease: Practice Guidelines. JAMA 1996, 275: 622-629. DOI: 10.1001/jama.1996.03530320046033.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsNonsteroidal antiinflammatory drugsRefractory ulcersUlcer patientsPeptic ulcerSuccessful H pylori eradicationConventional maintenance therapyConventional ulcer therapyH pylori eradicationPractice Parameters CommitteeUse of aspirinPeptic ulcer diseaseH pylori infectionAmerican Gastroenterological AssociationMaintenance therapyNSAID usePylori eradicationAntibiotic regimenSymptom reliefAntibiotic therapyUlcer diseaseRecurrence rateUlcer therapyConventional therapyPylori infectionDisease management approach